Top Markets
Coin of the day
MetaVia Inc. MetaVia Inc.

MetaVia Inc.

MTVA
Rang in Aktien #35877
Headquartered in Cambridge, Massachusetts, MetaVia Inc. operates as a... Headquartered in Cambridge, Massachusetts, MetaVia Inc. operates as a clinical-stage biotechnology company with a core focus on discovering and commercializing novel pharmaceutical solutions for cardiometabolic disorders. Its leading investigational drug, DA-1241, a unique G-Protein-Coupled Receptor 119 agonist, is currently undergoing Phase 2a clinical trials for metabolic dysfunction-associated steatohepatitis (MASH). This follows the successful completion of Phase 1 trials for type 2 diabetes mellitus (T2DM), and the compound holds promise for use as both a standalone therapy and in combination treatments. Another significant asset, DA-1726, an innovative oxyntomodulin analogue that functions as a dual agonist for GLP-1 and glucagon receptors, is presently in preclinical development specifically for treating obesity. MetaVia's broader therapeutic pipeline also includes ANA001, a distinct oral niclosamide formulation intended for moderate COVID-19 patients; NB-01, designed to address painful diabetic neuropathy; NB-02, targeting cognitive impairment; and Gemcabene, for the management of dyslipidemia. The company engages in strategic partnerships, notably a licensing agreement with Pfizer Inc. for the research, development, manufacturing, and commercialization of Gemcabene. Additionally, a joint research collaboration with Dong-A ST and ImmunoForge supports the advancement of DA-1726. The entity adopted its current name, MetaVia Inc., in November 2024, transitioning from its former identity as NeuroBo Pharmaceuticals, Inc.
Aktienkurs
$1.51
Zuletzt synchronisiert: 2026-08-14
Marktkapitalisierung
$3.32M
Veränderung (1 Tag)
3.42%
Veränderung (1 Jahr)
-78.55%
Land
US
Handel MetaVia Inc. (MTVA)

Kategorie

Preis MTVA mit Marktkapitalisierung von B
MetaVia Inc. MetaVia Inc.
MTVA
$1.51
Marktkapitalisierung von MetaVia Inc.(MTVA)
Marktkapitalisierung: $3.32M
Mit Stand August 2026 hat MetaVia Inc. eine Marktkapitalisierung von $3.32M. Das macht MetaVia Inc. laut unseren Daten zum 35877th wertvollsten Unternehmen der Welt nach Marktkapitalisierung. Die Marktkapitalisierung ist der Gesamtmarktwert aller ausstehenden Aktien eines börsennotierten Unternehmens und wird häufig verwendet, um den Unternehmenswert zu bestimmen.
Marktkapitalisierung von MetaVia Inc. von 2024 bis 2026
MTVA im Vergleich zu den Top 5 der beliebtesten stocks
Preis für MTVA Vermögenswert B Marktkapitalisierung von B Ergebnisse
MetaVia Inc. MetaVia Inc.
$2,476,400 $3.32M
$5.452T +163,999,879.82%
MetaVia Inc. MetaVia Inc.
$2,039,500 $3.32M
$4.490T +135,066,129.25%
MetaVia Inc. MetaVia Inc.
$1,890,688 $3.32M
$4.162T +125,211,057.07%
MetaVia Inc. MetaVia Inc.
$1,669,904 $3.32M
$3.676T +110,589,539.25%
MetaVia Inc. MetaVia Inc.
$1,286,852 $3.32M
$2.833T +85,221,874.59%